United States: Mintz Levin Health Care Qui Tam Update - August 2018

Overview of Qui Tam Activity

  • We identified 46 health care related qui tam cases that were unsealed in February and March 2018.
  • The government intervened in whole or in part in 14% of those unsealed cases, which was identical with the prior two-month period and is consistent with the overall intervention rate during the prior 12 months.
  • Of the 46 unsealed cases, only 17 were dismissed in their entirety. The other 29 remained active.
  • The 46 unsealed cases were filed in 38 different courts. Jurisdictions with the most unsealed cases were the Middle District of Florida (Jacksonville, Orlando, and Tampa) with six, the Northern District of Ohio (Cleveland) with three, and the District of Kansas, the Eastern District of Tennessee (Chattanooga and Knoxville), the Northern District of Illinois (Chicago), and the Southern District of Florida (Miami, Fort Lauderdale, and West Palm Beach) with two apiece.
  • Home health and hospice providers were defendants in seven of the cases. Seven cases were also brought against hospitals and hospital systems, and five cases were brought against pharmaceutical and biotech firms. Three of the unsealed cases named physicians or physician practice groups, while another three were brought against health insurers.
  • As is typically the case, former employees were again the most frequent relator type, accounting for 23 of the 46 unsealed cases. Current employees only brought three of the cases. Three cases were brought by defendants' business partners.
  • None of the cases was unsealed within the 60-day period specified by statute, although one was unsealed after 61 days. The longest time under seal was just over six years. The average time under seal for this group of unsealed cases was 851 days. Only five of the 46 unsealed cases were unsealed in less than one year.

Featured Cases

United States ex rel. Cleary v. Ioannides, No. 2:15-cv-14306-RLR (S.D. Fla.)

Complaint Filed: August 31, 2015

Complaint Unsealed: March 7, 2018

Intervention Status: The government intervened on December 4, 2017, for purposes of settlement.

Claims: False Claims Act ("FCA"), 31 U.S.C. § 3729 et seq.

Defendants' Businesses: Defendant is a dermatologist who practices through Tim Ioannides, M.D., LLC d/b/a Treasure Coast Dermatology, which is also a named defendant.

Relator: Patricia Cleary

Relator's Relationship to Defendants: The relator was a patient of Dr. Ioannides and Treasure Coast Dermatology.

Relator's Counsel: Iain Leslie Cooper Kennedy, Paul Thomas Reid, and Timothy Michael Moore of Shook, Hardy & Bacon L.L.P. and Theodore Charles Miloch, II of Infante Zumpano Hudson & Miloch LLC

Summary of Case: The relator, a patient of the defendant Ioannides, alleged that Ioannides billed and received payment from Medicare for a procedure he did not perform on her. Specifically, the relator alleged that she saw Ioannides, a dermatologist, for removal of a potentially cancerous lesion from her forehead. However, Ioannides billed the procedure as flap surgery, a procedure performed by plastic surgeons that involves moving a muscle and skin flap from a donor site to a recipient site without disconnecting the flap's existing blood supply. The procedure is commonly performed on patients who have received mastectomies and cannot be performed on a patient's forehead. The relator also contended that Ioannides committed this same fraud numerous times beginning at least as early as 2012. Citing information obtained from the publically available CMS Medicare database, the relator asserted that Ioannides was the country's top biller for flap surgeries in 2012 and 2013. The relator charged that Ioannides violated the FCA by fraudulently billing Medicare for flap surgeries she claimed he had not performed.

Current Status: The United States intervened on December 4, 2017, and entered into a Settlement Agreement with the defendants on December 21, 2017. Pursuant to this Settlement Agreement, defendants were to pay $2,500,000 to the United States. The settlement amount was payable in installments, due in full by January 31, 2018. The relator received 19% of the total settlement amount. The complaint was dismissed and unsealed in part on March 7, 2018.

Reasons to Watch: This is an interesting case in several respects. It is relatively rare for patients to serve as relators, but the number of patient relators has been growing in recent years. It is also interesting to see a large defense-oriented law firm, Shook Hardy, serving as one of the relator's lawyers. But possibly the most interesting aspect of this case is the use of data from the CMS Medicare database to support the relator's claims. A 1979 injunction prohibited CMS from disclosing physician-identifying data. In 2013, however, that injunction was lifted, making it possible to link Medicare claims data to physicians who performed the services. This case provides an example of how relators can make use of that data to attempt to demonstrate the extent of allegedly fraudulent billings by physicians alleged to have violated the FCA. It is likely that growing numbers of relators will mine the CMS Medicare database for similar patterns of activity in order to support qui tam litigation.

United States ex rel. Knopf v. Agevital Pharmacy, LLC, No. 8:15-cv-02591-CEH-JSS (M.D. Fla.)

Complaint Filed: November 4, 2015

Complaint Unsealed: March 9, 2018

Intervention Status: On March 8, 2018, the government entered a notice that it is not intervening at this time.

Claims: FCA

Defendants' Businesses: Defendant AgeVital Pharmacy, LLC, is a compounding pharmacy that provides compounded pharmaceuticals to Medicare beneficiaries, among other customers. Defendant Jean Wilson, FNP-BC, is a nurse practitioner licensed in Maryland, New Jersey, New York, and North Carolina.

Relator: Manfred Knopf

Relator's Relationship to Defendants: The relator allegedly received unsolicited compounded pharmaceuticals that he neither wanted nor needed from AgeVital.

Relator's Counsel: Sean Keefe and Elaine Stromgren of James Hoyer, P.A., David Caputo and David Williams of Kline & Specter, P.C., and Claudine Q. Homolash of CQH Firm.

Summary of Case: The relator resides in New Jersey. In mid-2014, he slipped and suffered an injury that caused him pain. Between July and December 2014, relator sought and received treatment from several providers for his injury. The relator alleged that he received at least three unsolicited phone calls from AgeVital between August and December 2014. These callers were aware of the relator's medical history, requested his insurance information and date of birth, and stated they wanted to help him. Ultimately, the relator received three shipments containing two compounded pharmaceuticals. The prescriber listed on the containers was "Dr. Jean Wilson," yet the relator alleged that he had never heard of this person nor had he been treated by someone named "Dr. Jean Wilson." The NPI number associated with "Dr. Jean Wilson" belongs to Ms. Wilson, a nurse practitioner with a business mailing address in Bayonne, New Jersey. The relator asserted that he neither requested nor sought these treatments and that Medicare paid AgeVital over $37,000 for the compounded pharmaceuticals. The relator asserted that he neither requested nor sought these treatments and that Medicare paid AgeVital over $37,000 for the compounded pharmaceuticals. He also charged that the described solicitation and billing practices were fraudulent and that the defendants conspired to submit false claims to the federal government in violation of the FCA.

Current Status: In early March 2018, the United States decided not to intervene "at this time."

Reasons to Watch: This is another case in which the relator is a patient. In this particular case, the FCA allegations arose from alleged fraud committed not only against the government but also against the patient-relator. This case typifies the increasing use of the FCA to target common law fraud.

United States ex rel. Kaplan v. Northern Metropolitan, Inc., No. 16-cv-2180-ALC (S.D.N.Y.)

Complaint Filed: March 24, 2016

Complaint Unsealed: March 8, 2018

Intervention Status: Intervention by the United States on March 7, 2018

Claims: FCA; State of New York False Claims Act, New York Finance Law, § 187 et seq.

Defendants' Businesses: Defendant Northern Metropolitan, Inc. ("NMET") is a residential health care facility located in Monsey, New York and a wholly owned subsidiary of defendant NCH Healthcare System, Inc. Defendant Northern Riverview Health Care Center, Inc. ("NRV") is a Section 501(c)(3) entity, which is the operator of Riverside Nursing Home. Defendant Northern Services Group, Inc. ("NSG") is a shared services parent organization created to coordinate the elder care of Chevre Liady Nusach Hoary. Defendant Northern Metropolitan Foundation for Healthcare, Inc. ("NMFHC") is a Section 501(c)(3) entity, which replaced NSG as the corporate member of NMET and NRV. Defendant Chevre Liady Nusach Hoary ("CLNH") is a not-for-profit religious organization, which is the owner of NMET.

Relator: Sonny Kaplan

Relator's Relationship to Defendants: Mr. Kaplan was a full-time financial employee of NRV beginning on January 10, 2000.

Relator's Counsel: Philip Roy Michael of Michael Law Group and Mark H. Schwartz of the Law Office or Mark H. Schwartz.

Summary of Case: The relator alleged that his superiors at NRV, several years after being appointed by the New York State Department of Health ("DOH") as the receiver of Riverside Nursing Home, became aware of a double-counted Medicaid Transfer Price ("MATP") of $2,180,000, totaling $4,360,000. A MATP consists of reimbursement, paid annually, over a period of 20 or 30 years, until the full amount of un-depreciated capital costs incurred by an acquiring health care provider is fully repaid. The relator alleged that his superiors at NRV were aware of the double-counted MATP but nonetheless retained the double-counted MATP, which was being paid year-to-year to NRV. The relator generally asserted that no NRV accountant or operator informed the DOH or federal government of the double-counted MATP. The relator also alleged that beginning in 1998, as a result of the error in the MATP calculation, Medicaid made excessive depreciation-reimbursement payments to NRV. In addition, the relator contended that his superiors at NRV informed him of their justification for failing to disclose the error to DOH or the federal government, suggesting that because of a systemic unfairness in the manner in which DOH reimbursed facilities, the error resulted in a balanced reimbursement to NRV.

Current Status: On March 7, 2018, the United States intervened in the case, and the complaint was unsealed on March 7, 2018. On March 12, 2018, a New York State Stipulation and Order of Settlement and Dismissal and a federal Stipulation and Order of Settlement and Dismissal were entered by the Court. In the stipulations, the defendants admitted to reporting erroneous capital costs of $2,183,679, resulting in "hundreds of thousands of dollars" in overpayments to the defendants. Under the settlement, the defendants paid an aggregate amount of $500,000 to the federal government and the State of New York, with $288,313.82 to be paid to New York and $211,686.18 to be paid to the United States. The relator's share of the New York settlement was $51,896.49, and the United States paid the relator $42,337.24.

Reasons to Watch: Kaplan provides insight into the risks that a party may face in failing to provide authorities with voluntary disclosure of known overpayment amounts. The case illustrates a scenario where a medical services provider intentionally concealed a known repayment obligation, only to have their unlawful conduct reported by a former employee.

United States ex rel. Kelly v. Bromedicon, Inc., No. 2:13-cv-7635-TJS (E.D. Pa.)

Complaint Filed: December 30, 2013

Complaint Unsealed: March 13, 2018

Intervention Status: Intervention by the United States on March 8, 2018.

Claims: FCA

Defendants' Businesses: Bromedicon, Inc. ("Bromedicon") is a corporation, established in 1986 and owned by James Brogan ("Brogan"). Bromedicon primarily engages in the provision of IntraOperative Neurophysiological Monitoring ("IOM"). IOM involves the remote monitoring, by a qualified medical professional (known as a "qualified interpretation professional" or "QIP"), of a patient's neurological status and neural structures during surgery to assist in the prevention of damage to that patient's nervous system. Bromedicon provides the service to over 3,000 patients per year.

Relators: Dianna Kelly

Relator's Relationship to Defendants: Ms. Kelly was employed by Defendant as an office manager.

Relator's Counsel: Sidney L. Gold of Sidney L. Gold & Assoc. P.C.; Neelima Vanguri of Sidney L. Gold & Assoc. P.C.

Summary of Case: The relator alleged that Bromedicon billed Medicare for IOM services that were never provided. The relator claimed that Bromedicon provided IOM services without necessarily having QIPs available to perform all contracted monitoring services. Where a QIP was unable to monitor a procedure, Bromedicon purportedly had a QIP sign a fabricated interpretation report associated with the procedure that represented to Medicare that the IOM service was, in fact, provided to the patient. The relator further alleged that Bromedicon billed for more IOM services than were appropriate, or even possible, given scheduling and staffing constraints. The relator also asserted that Bromedicon inflated the time that QIPs spent performing IOM services and billed Medicare for the full – inflated – time. The relator claimed to have informed Bromedicon about these practices, but Bromedicon failed to report the relator's findings to the Office of the Inspector General of the Department of Health and Human Services ("OIG") or the Department of Justice ("DOJ").

Current Status: On March 8, 2018, the United States intervened in the case. The complaint was unsealed five days later on March 13, 2018. A subsequent sealed order entered on April 26, and no further proceedings have occurred on the public record.

Reasons to Watch: Kelly highlights the potential risks associated with providing patient services remotely. As telemedicine becomes more prevalent, there is an increased risk of actual – or claimed – failure to provide remote services. Providers that provide services remotely need to develop good systems and practices to ensure accountability by remote providers, both to avoid fraud and to defend against fraud claims. And all types of providers should be mindful of the risk, as alleged here, that failure to act on an employee's reporting of potential fraud and abuse can lead to a whistleblower lawsuits.

Health Care Qui Tam Litigation Trends

Mintz Levin maintains a database of unsealed health care qui tam actions. This enables us to follow and analyze trends in the cases that have been unsealed. The following are some trends in qui tam filings against health care-related entities in the 12 months that ended June 30, 2018:

Where were cases filed? Although cases were unsealed in jurisdictions throughout the country, some interesting trends have emerged as to jurisdictions where the most cases have been unsealed:

For the 12-month period that ended on June 30, the Middle District of Florida (Tampa, Orlando, and Jacksonville) continued to be the leading jurisdiction for unsealed cases, with 20 cases being unsealed over that time frame. Following closely behind was the Central District of California (including Los Angeles and Santa Barbara), where 17 cases were unsealed. Other courts with 10 or more cases unsealed in that 12-month period were the District of Columbia, the Eastern District of New York (Brooklyn, Queens, and Long Island), and the Southern District of Florida (Miami, Fort Lauderdale, and West Palm Beach).

Who brought the cases? The ranks of relators are beginning to diversify. Current and former employees – mostly the latter – dominate the ranks of relators, accounting for 57% of all cases. But significant numbers of relators are now found among customers, industry experts, business partners, consultants, and patients.

Intervention rates continue to be extremely low, with the government electing to intervene only 17% of cases unsealed in the 12 months that ended June 30, 2018.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Kevin M. McGinty
Bridgette A. Keller
Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions